Gene

ATXN7L1

ataxin 7 like 1

Explore in graph →CI-GENE-00021471HGNC:22210 ENSG00000146776 NCBI 222255 Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ATXN7L1 Fusion1
Crizotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID7793 Case Report of a a 56-year-old female (never-smoker) patient with stage IV NSCLC. NGS revealed a MET–ATXN7L1 fusion. No additional known driver gene alterations were identified. Following progression … (full text at CIViC) PMID 30339198 · Zhu et al., 2018 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (6)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved6 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Clear Cell Renal Cell Carcinoma (DFCI, Science 2019) ccrcc_dfci_2019	Clear Cell Renal Cell Carcinoma	Ssm	4

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.
· Ann Oncol · 2018 · PMID 30339198 · validated civic_curation pubmed